{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:23:22Z","timestamp":1769523802694,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,6]]},"DOI":"10.7759\/cureus.50072","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T01:45:42Z","timestamp":1701913542000},"source":"Crossref","is-referenced-by-count":1,"title":["Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy for Refractory Colorectal Liver Metastasis: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Faiza H","family":"Soomro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafsa A","family":"Osman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merna","family":"Haridi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie A","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sana M","family":"Dayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umaima","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaiyat","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaitanya S","family":"Puvvada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann Kashmer","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00044-9","article-title":"Global, regional, and national burden of colorectal cancer and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"7","author":"GBD 2019 Colorectal Cancer Collaborators","year":"2022","unstructured":"GBD 2019 Colorectal Cancer Collaborators. Global, regional, and national burden of colorectal cancer and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022, 7:627-47. 10.1016\/S2468-1253(22)00044-9","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref3","article-title":"Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer","volume":"33","author":"Narayanan G","year":"2013","unstructured":"Narayanan G, Barbery K, Suthar R, Guerrero G, Arora G. Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer. Anticancer Res. 2013, 33:2077-83.","journal-title":"Anticancer Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2018.10.018","article-title":"Regional therapies for the treatment of primary and metastatic hepatic tumors: a disease-based review of techniques and critical appraisal of current evidence","volume":"217","author":"Johnson BW","year":"2019","unstructured":"Johnson BW, Wright GP. Regional therapies for the treatment of primary and metastatic hepatic tumors: a disease-based review of techniques and critical appraisal of current evidence. Am J Surg. 2019, 217:541-5. 10.1016\/j.amjsurg.2018.10.018","journal-title":"Am J Surg"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.5278","article-title":"Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy","volume":"27","author":"Kopetz S","year":"2009","unstructured":"Kopetz S, Chang GJ, Overman MJ, et al.. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009, 27:3677-83. 10.1200\/JCO.2008.20.5278","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2017.05.003","article-title":"Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: a\u00a0systematic review","volume":"26","author":"Akinwande O","year":"2017","unstructured":"Akinwande O, Dendy M, Ludwig JM, Kim HS. Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: a\u00a0systematic review. Surg Oncol. 2017, 26:268-75. 10.1016\/j.suronc.2017.05.003","journal-title":"Surg Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-7-80","article-title":"Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report","volume":"7","author":"Martin RC","year":"2009","unstructured":"Martin RC, Robbins K, Tomalty D, et al.. Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol. 2009, 7:80. 10.1186\/1477-7819-7-80","journal-title":"World J Surg Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/539795","article-title":"Transarterial chemoembolization of metastatic colorectal carcinoma with drug-eluting beads, irinotecan (DEBIRI): multi-institutional registry","volume":"2009","author":"Martin RC","year":"2009","unstructured":"Martin RC, Joshi J, Robbins K, Tomalty D, O'Hara R, Tatum C. Transarterial chemoembolization of metastatic colorectal carcinoma with drug-eluting beads, irinotecan (DEBIRI): multi-institutional registry. J Oncol. 2009, 2009:539795. 10.1155\/2009\/539795","journal-title":"J Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1573","article-title":"Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301","volume":"24","author":"Chen HX","year":"2006","unstructured":"Chen HX, Mooney M, Boron M, et al.. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol. 2006, 24:3354-60. 10.1200\/JCO.2005.05.1573","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.02.008","article-title":"Molecular biomarkers in the personalized treatment of colorectal cancer","volume":"14","author":"Sinicrope FA","year":"2016","unstructured":"Sinicrope FA, Okamoto K, Kasi PM, Kawakami H. Molecular biomarkers in the personalized treatment of colorectal cancer. Clin Gastroenterol Hepatol. 2016, 14:651-8. 10.1016\/j.cgh.2016.02.008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem E","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, et al.. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016, 27:1386-422. 10.1093\/annonc\/mdw235","journal-title":"Ann Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2217\/hep-2019-0010","article-title":"Updates of colorectal cancer liver metastases therapy: review on DEBIRI","volume":"7","author":"Fiorentini G","year":"2020","unstructured":"Fiorentini G, Sarti D, Nani R, Aliberti C, Fiorentini C, Guadagni S. Updates of colorectal cancer liver metastases therapy: review on DEBIRI. Hepat Oncol. 2020, 7:HEP16. 10.2217\/hep-2019-0010","journal-title":"Hepat Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-010-1288-5","article-title":"Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study","volume":"18","author":"Martin RC","year":"2011","unstructured":"Martin RC, Joshi J, Robbins K, et al.. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol. 2011, 18:192-8. 10.1245\/s10434-010-1288-5","journal-title":"Ann Surg Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990215)85:4<786::AID-CNCR5>3.0.CO;2-9","article-title":"A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma","volume":"85","author":"Rothenberg ML","year":"1999","unstructured":"Rothenberg ML, Cox JV, DeVore RF, et al.. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer. 1999, 85:786-95. 10.1002\/(SICI)1097-0142(19990215)85:4&lt;786::AID-CNCR5&gt;3.0.CO;2-9","journal-title":"Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1128","article-title":"Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer","volume":"14","author":"Rothenberg ML","year":"1996","unstructured":"Rothenberg ML, Eckardt JR, Kuhn JG, et al.. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol. 1996, 14:1128-35. 10.1200\/JCO.1996.14.4.1128","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2006.09.002","article-title":"Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties","volume":"30","author":"Taylor RR","year":"2007","unstructured":"Taylor RR, Tang Y, Gonzalez MV, Stratford PW, Lewis AL. Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci. 2007, 30:7-14. 10.1016\/j.ejps.2006.09.002","journal-title":"Eur J Pharm Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-015-3386-9","article-title":"Efficacy and toxicity of hepatic intra-arterial drug-eluting (irinotecan) bead (DEBIRI) therapy in irinotecan-refractory unresectable colorectal liver metastases","volume":"40","author":"Bhutiani N","year":"2016","unstructured":"Bhutiani N, Akinwande O, Martin RC 2nd. Efficacy and toxicity of hepatic intra-arterial drug-eluting (irinotecan) bead (DEBIRI) therapy in irinotecan-refractory unresectable colorectal liver metastases. World J Surg. 2016, 40:1178-90. 10.1007\/s00268-015-3386-9","journal-title":"World J Surg"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, et al.. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021, 372:n160. 10.1136\/bmj.n160","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-018-2017-x","article-title":"Transarterial embolization with small-size particles loaded with irinotecan for the treatment of colorectal liver metastases: results of the MIRACLE III study","volume":"41","author":"Mauri G","year":"2018","unstructured":"Mauri G, Varano GM, Della Vigna P, et al.. Transarterial embolization with small-size particles loaded with irinotecan for the treatment of colorectal liver metastases: results of the MIRACLE III study. Cardiovasc Intervent Radiol. 2018, 41:1708-15. 10.1007\/s00270-018-2017-x","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-017-0890-9","article-title":"Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization","volume":"34","author":"Scevola G","year":"2017","unstructured":"Scevola G, Loreni G, Rastelli M, Sposato S, Ramponi S, Miele V. Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization. Med Oncol. 2017, 34:37. 10.1007\/s12032-017-0890-9","journal-title":"Med Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-019-02219-4","article-title":"Transarterial chemoembolisation of colorectal liver metastases with irinotecan-loaded beads: a bi-institutional analysis of 125 treatments in 53 patients","volume":"42","author":"Ngo A","year":"2019","unstructured":"Ngo A, von Stempel C, Corbo B, et al.. Transarterial chemoembolisation of colorectal liver metastases with irinotecan-loaded beads: a bi-institutional analysis of 125 treatments in 53 patients. Cardiovasc Intervent Radiol. 2019, 42:979-90. 10.1007\/s00270-019-02219-4","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-021-03039-1","article-title":"Small-size (40\u00a0\u00b5m) beads loaded with irinotecan in the treatment of patients with colorectal liver metastases","volume":"45","author":"Mauri G","year":"2022","unstructured":"Mauri G, Rossi D, Frassoni S, et al.. Small-size (40\u00a0\u00b5m) beads loaded with irinotecan in the treatment of patients with colorectal liver metastases. Cardiovasc Intervent Radiol. 2022, 45:770-9. 10.1007\/s00270-021-03039-1","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2019.05.14","article-title":"Chemoembolization with CalliSpheres drug-eluting beads loaded with irinotecan in the treatment of unresectable colorectal cancer liver metastases: preliminary results in 16 cases","volume":"8","author":"Kong J","year":"2019","unstructured":"Kong J, Li Y, Bian YJ, Guo JX, Zhang YF. Chemoembolization with CalliSpheres drug-eluting beads loaded with irinotecan in the treatment of unresectable colorectal cancer liver metastases: preliminary results in 16 cases. Transl Cancer Res. 2019, 8:856-66. 10.21037\/tcr.2019.05.14","journal-title":"Transl Cancer Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2018.08.010","article-title":"Irinotecan-eluting 75-150-\u03bcm embolics lobar chemoembolization in patients with colorectal cancer liver metastases: a prospective single-center phase I study","volume":"29","author":"Fereydooni A","year":"2018","unstructured":"Fereydooni A, Letzen B, Ghani MA, et al.. Irinotecan-eluting 75-150-\u03bcm embolics lobar chemoembolization in patients with colorectal cancer liver metastases: a prospective single-center phase I study. J Vasc Interv Radiol. 2018, 29:1646-53.e5. 10.1016\/j.jvir.2018.08.010","journal-title":"J Vasc Interv Radiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-020-02438-0","article-title":"Does bead size affect patient outcome in irinotecan-loaded beads chemoembolization plus systemic chemotherapy regimens for liver-dominant colorectal cancer? Results of an observational study","volume":"43","author":"Boeken T","year":"2020","unstructured":"Boeken T, Moussa N, Pernot S, et al.. Does bead size affect patient outcome in irinotecan-loaded beads chemoembolization plus systemic chemotherapy regimens for liver-dominant colorectal cancer? Results of an observational study. Cardiovasc Intervent Radiol. 2020, 43:866-74. 10.1007\/s00270-020-02438-0","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref26","article-title":"Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: a systematic review","volume":"1","author":"Akinwande O","year":"2017","unstructured":"Akinwande O, Dendy M, Ludwig JM, Kim HS. Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: a systematic review. Surgical Oncology. 2017, 1:268-75.","journal-title":"Surgical Oncology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20151060","article-title":"Current strategies in interventional oncology of colorectal liver metastases","volume":"89","author":"Gruber-Rouh T","year":"2016","unstructured":"Gruber-Rouh T, Marko C, Thalhammer A, et al.. Current strategies in interventional oncology of colorectal liver metastases. Br J Radiol. 2016, 89:20151060. 10.1259\/bjr.20151060","journal-title":"Br J Radiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0025","article-title":"DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer","volume":"15","author":"Di Noia V","year":"2019","unstructured":"Di Noia V, Basso M, Marsico V, et al.. DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer. Future Oncol. 2019, 15:2349-60. 10.2217\/fon-2017-0025","journal-title":"Future Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0917-4","article-title":"Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a phase 2 study","volume":"123","author":"Pernot S","year":"2020","unstructured":"Pernot S, Pellerin O, Artru P, et al.. Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a phase 2 study. Br J Cancer. 2020, 123:518-24. 10.1038\/s41416-020-0917-4","journal-title":"Br J Cancer"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27859","article-title":"Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma","volume":"119","author":"Buijs M","year":"2013","unstructured":"Buijs M, Reyes DK, Pawlik TM, et al.. Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer. 2013, 119:1042-9. 10.1002\/cncr.27859","journal-title":"Cancer"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11824","article-title":"Chemoembolization alone or associated with bevacizumab for therapy of colorectal cancer metastases: preliminary results of a randomized study","volume":"34","author":"Fiorentini G","year":"2020","unstructured":"Fiorentini G, Sarti D, Nardella M, Inchingolo R, Nestola M, Rebonato A, Guadagni S. Chemoembolization alone or associated with bevacizumab for therapy of colorectal cancer metastases: preliminary results of a randomized study. In Vivo. 2020, 34:683-6. 10.21873\/invivo.11824","journal-title":"In Vivo"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s13187-015-0845-9","article-title":"Patients\u2019 preferences for information about the benefits and risks of second-line palliative chemotherapy and their oncologist\u2019s awareness of these preferences","volume":"31","author":"Oostendorp LJ","year":"2016","unstructured":"Oostendorp LJ, Ottevanger PB, van de Wouw AJ, Honkoop AH, Los M, van der Graaf WT, Stalmeier PF. Patients\u2019 preferences for information about the benefits and risks of second-line palliative chemotherapy and their oncologist\u2019s awareness of these preferences. J Cancer Educ. 2016, 31:443-8. 10.1007\/s13187-015-0845-9","journal-title":"J Cancer Educ"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2013.05.055","article-title":"Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review","volume":"24","author":"Richardson AJ","year":"2013","unstructured":"Richardson AJ, Laurence JM, Lam VW. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review. J Vasc Interv Radiol. 2013, 24:1209-17. 10.1016\/j.jvir.2013.05.055","journal-title":"J Vasc Interv Radiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/131171-drug-eluting-bead-irinotecan-debiri-therapy-for-refractory-colorectal-liver-metastasis-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:09:35Z","timestamp":1707509375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/131171-drug-eluting-bead-irinotecan-debiri-therapy-for-refractory-colorectal-liver-metastasis-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.50072","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,6]]}}}